Compare XOM & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XOM | TMO |
|---|---|---|
| Founded | 1870 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Industrial Machinery/Components |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 518.3B | 176.8B |
| IPO Year | 2005 | 1996 |
| Metric | XOM | TMO |
|---|---|---|
| Price | $156.44 | $464.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 19 |
| Target Price | $141.40 | ★ $639.83 |
| AVG Volume (30 Days) | ★ 15.6M | 1.9M |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.68% | 0.36% |
| EPS Growth | N/A | ★ 7.32 |
| EPS | 6.70 | ★ 17.74 |
| Revenue | ★ $332,238,000,000.00 | $20,918,000,000.00 |
| Revenue This Year | $0.97 | $6.22 |
| Revenue Next Year | $6.11 | $5.10 |
| P/E Ratio | ★ $22.94 | $26.87 |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $97.80 | $385.46 |
| 52 Week High | $159.61 | $643.99 |
| Indicator | XOM | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 22.36 |
| Support Level | $112.54 | $451.48 |
| Resistance Level | $158.27 | $497.64 |
| Average True Range (ATR) | 3.71 | 12.51 |
| MACD | -0.32 | -1.64 |
| Stochastic Oscillator | 75.30 | 0.43 |
ExxonMobil is an integrated oil and gas company that explores for, produces, and refines oil worldwide. In 2024, it produced 3.0 million barrels of liquids and 8.1 billion cubic feet of natural gas per day. At the end of 2024, reserves were 19.9 billion barrels of oil equivalent, 69% of which were liquids. The company is one of the world's largest refiners, with a total global refining capacity of 4.3 million barrels of oil per day, and is one of the world's largest manufacturers of commodity and specialty chemicals.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).